About ArpIda
ArpIda is a Healthcare company based in Reinach (Switzerland) founded in 1997, and was acquired by Evolva in September 2009. Drugs for treating microbial resistance are developed by the company. ArpIda has raised $90.4 million across 3 funding rounds from investors including Evolva, Carlsberg Group and O-Bank. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial.
Company details
ArpIda was founded in 1997 and is based in Reinach, Switzerland. Operations center on the pharmaceutical sector, with emphasis placed on antibiotics to address microbial resistance. The lead product candidate, intravenous iclaprim, is designed for hospital-treated severe infections, such as those from methicillin-resistant Staphylococcus aureus (MRSA). Development efforts target unmet needs in infectious disease management.
- Headquarters Reinach, Switzerland
- Stage Acquired
- SectorsHealthcare
- Website arpida.com
- Social LinkedIn
- Acquired by Evolva (Sep 2009)
Funding Insights of ArpIda
ArpIda has successfully raised a total of $90.4M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $26.4 million completed in October 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90.4M
- Total Rounds 3
- Last Round Series C — $26.4M
- First Round $23M
(Nov 2000)
- Investors Count 7
All 3 funding rounds of ArpIda with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2004 | $26.4M | Series C | – | Carlsberg Group, LD Fonde | |
| May 2004 | $41M | Series C | – | – | – |
| Nov 2000 | $23M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in ArpIda
ArpIda has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Evolva, Carlsberg Group and O-Bank.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector-agnostic investments are made in early-stage Asia Pacific startups. | 1959 | cdibcapitalgroup.com | Taipei, Taiwan | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
| dankap.dk | ||||
Beers are brewed and distributed internationally by Carlsberg Group. | 1847 | carlsberggroup.com | Copenhagen, Denmark | |
Administers holiday and hardship funds for Danish employees and employers. | 1980 | ld.dk | Hojbjerg, Denmark | |
Commercial banking services are provided by O-Bank in Taiwan. | 1999 | o-bank.com | Taipei, Taiwan | |
| slsinvest.com | ||||
Producer of natural and functional ingredients for food, beverage and healthcare products | 2004 | evolva.com | Reinach, Switzerland |
Investor details for ArpIda
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ArpIda
5 dated milestones of ArpIda across 12 years, from founding to its latest funding, stage changes and deals.
- Founded ArpIda is founded.
- Funding First funding round of $23.0M.
- Funding Latest funding round, Series C, of $26.4M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Evolva.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ArpIda
ArpIda was founded in 1997 and raised its 1st funding round 3 years after it was founded.
ArpIda is headquartered in Reinach, Switzerland. It is registered at Reinach, Basel-landschaft, Switzerland.
ArpIda is a funded company, having raised a total of $90.4M across 3 funding rounds to date. The company's 1st funding round was a Series A of $23M, raised on Nov 2000.
ArpIda was founded in 1997 and is based in Reinach, Switzerland. Operations center on the pharmaceutical sector, with emphasis placed on antibiotics to address microbial resistance. The lead product candidate, intravenous iclaprim, is designed for hospital-treated severe infections, such as those from methicillin-resistant Staphylococcus aureus (MRSA). Development efforts target unmet needs in infectious disease management.
ArpIda has 8 investors. Key investors include Evolva, Carlsberg Group, O-Bank, CDIB Capital Group, and LD Fonde.
Yes. ArpIda was acquired by Evolva in September 2009.